Matt Layton, M.D., Ph.D.
Matt Layton wears several hats on the Riverpoint campus.
He’s a clinical associate professor in the WWAMI medical education program.
He's a psychiatrist who works to incorporate lessons about human behavior into a heavily science-based first-year medical school curriculum. He helps prospective doctors understand how the way people behave affects their health.
He directs the resident doctors in the University of Washington Medical School’s psychiatry program at Sacred Heart Medical Center. While there, he also works with third-year medical students in their six-week psychiatry clerkships.
Dr. Layton is the medical director for the WSU College of Nursing’s Program of Excellence in the Addictions. He has a Ph.D. in pharmacology. His current research focuses on the psychological and physiological changes in smokers during the first few days after they quit smoking. (plus one or two other research project(s) that Matt’s working on)
He’s also involved in training rural primary care doctors, physicians assistants and nurses to work with patients who have depression, anxiety and drug addictions.
Dr. Layton is a Kansas native who directed Spokane Mental Health for eight years. Since coming to WSU Spokane in the fall of 2008, he has won ‘Outstanding Faculty’ awards given by the UW physician assistant program and first-year Spokane medical students.
Dr. Layton’s active research:
Neuroactive Steroid Hormones in Smoking Cessation (Layton, PI); 08/01/10- 7/31/11; Washington State University – Spokane Seed Grant
Neuroactive Steroid Hormones in Methamphetamine and Cocaine Dependence (Layton, PI); 08/01/10-7/31/11; Washington State University – Spokane Program of Excellence in the Addictions Seed Grant
Methamphetamine Initiative Grant (Roll, PI); 03/11/09 – 03/10/12; Department of Justice; Co-Investigator
Center of Excellence in Rural Mental Health and Substance Abuse Treatment (Roll, PI); 08/16/09 – 08/15/13; Washington State Life Sciences Discovery Fund; Co-Investigator
NIDA National Drug Abuse Treatment Clinical Trials Network: Pacific Northwest Node (Donovan & Roll, Co-PIs); 2010-2014; Co-Investigator
